Flurbiprofen axetil

Overview

Flurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
The Effect of Enhanced Recovery After Surgery in Endoscopic Sinus Surgery	2019/08/07	NCT04048070	Not Applicable	Completed	Beijing Tongren Hospital
Postoperative Pain and Discomfort After Orbital Decompression	2018/06/19	NCT03562611	Not Applicable	Completed	Sun Yat-sen University
Nalbuphine and Flurbiprofen for Oculoplastic Surgery	2018/02/06	NCT03422887	Not Applicable	Completed	Sun Yat-sen University
Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery	2017/06/27	NCT03200600	Phase 4	Terminated	Peking University First Hospital
Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery	2017/06/01	NCT03172988	Phase 4	Terminated	Peking University First Hospital
Dezocine for Prevention of Catheter-related Bladder Discomfort	2017/05/10	NCT03147066	Phase 4	Completed	Jian-jun Yang
Analgesia Effects of Nalbuphine vs Sulfentanil	2015/11/13	NCT02604797	Not Applicable	UNKNOWN	Fudan University
Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients	2014/01/23	NCT02043366	Not Applicable	Completed	Tianjin Medical University General Hospital
Flurbiprofen Axetil for Uterine Contraction Pain	2008/07/30	NCT00725218	Phase 4	Completed	Nanjing Medical University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

HSK21542 Demonstrates Superior Efficacy in Two Phase 3 Trials for Postoperative Pain Management

2 months ago

• HSK21542, a novel kappa opioid receptor agonist, demonstrated statistically significant superiority over placebo in reducing postoperative pain intensity in two phase 3 trials involving 658 patients across 47 centers in China. • The drug showed non-inferiority to tramadol while exhibiting a markedly better safety profile, with significantly lower incidences of nausea (10.1% vs 41.9%) and vomiting (8.5% vs 38.0%) compared to tramadol. • Patients receiving HSK21542 required fewer rescue analgesics and reported higher satisfaction scores, with the drug maintaining efficacy for up to 24 hours post-administration. • The favorable safety profile included no respiratory depression events and reduced gastrointestinal side effects, positioning HSK21542 as a promising alternative to traditional opioid therapies.

Dexmedetomidine Nasal Spray Shows Promise in Reducing Emergence Agitation After ENT Surgery

9 months ago

A randomized, double-blind, placebo-controlled trial is underway to evaluate dexmedetomidine nasal spray's effectiveness in reducing emergence agitation (EA) in adults after ENT surgery.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access